Osamu Kunii, CEO of the GHIT Fund, and leaders of globally active companies will engage in a dialogue about solutions to global health issues and the role Japan should play in this area. This dialogue was featured as a collaborative article in Forbes JAPAN.

For the fourth edition in 2025, we are honored to welcome Masanori Kawasaki, Senior Vice President & Operating Officer, Associate General Manager (Research) at Otsuka Pharmaceutical Co., Ltd.

Mr. Kawasaki has devoted much of his career to the development of innovative treatment for tuberculosis, most notably leading the efforts that resulted in delamanid—a groundbreaking treatment launched by Otsuka in 2014—as the first new TB drug in nearly 40 years.

With tuberculosis continuing to affect still an estimated 10.8 million people and claim approximately 1.25 million lives worldwide each year, Mr. Kawasaki offers his perspectives on the driving forces behind drug discovery, Japan’s contributions to global TB research, and the vital role of partnerships in addressing urgent public health challenges.

Forbes JAPAN x GHIT Fund collaboration page (only in Japanese)

Read the article from the link below:

Forbes JAPAN BrandVoice (only in Japanese)